3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
370
Neoplasms
253
Carcinoma, Non-Small-Cell Lung
224
Prostatic Neoplasms
192
Lung Neoplasms
142
Colorectal Neoplasms
139
Neoplasm Metastasis
132
Pancreatic Neoplasms
131
Leukemia, Myeloid, Acute
126
Multiple Myeloma
123
Lymphoma
115
Carcinoma, Hepatocellular
111
Ovarian Neoplasms
98
Melanoma
97
Recurrence
93
Leukemia
89
Head and Neck Neoplasms
89
Leukemia, Lymphocytic, Chronic, B-Cell
86
Brain Neoplasms
86
Precursor Cell Lymphoblastic Leukemia-Lymphoma
79
Glioblastoma
77
Lymphoma, Non-Hodgkin
73
Squamous Cell Carcinoma of Head and Neck
71
Lymphoma, Follicular
70
Lymphoma, Large B-Cell, Diffuse
66
Colonic Neoplasms
66
Carcinoma, Renal Cell
62
Hematologic Neoplasms
59
Sarcoma
55
Glioma
53
Interventions
olorofim
1
Caspofungin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Interventional
×
Invasive Pulmonary Aspergillosis
×
Clear all
NCT02856178
2018-02-15
SAFEGUARD
F2G Biotech GmbH
Phase 1/2
Withdrawn